| Literature DB >> 33335509 |
Jiaqi Wei1,2, Jianhua Hou1,2, Bin Su1,2, Taiyi Jiang1,2, Caiping Guo1, Wen Wang1, Yang Zhang1,2, Biru Chang3,4, Hao Wu1,2, Tong Zhang1,2.
Abstract
Background: The HIV associated mortality is decreasing in most countries due to the widespread use of antiretroviral therapy. However, HIV-associated neurocognitive disorder (HAND) remains a problematic issue that lowers the quality of life and increases the public health burden among people living with HIV. The prevalence of HAND varies across studies and selected samples. Therefore, we aimed to quantitatively summarize the pooled prevalence of Frascati-criteria-based HAND and to explore the potential demographic, clinical, and immunological factors.Entities:
Keywords: Frascati criteria; HIV-associated neurocognitive disorder; meta-analysis; prevalence; systematic review
Year: 2020 PMID: 33335509 PMCID: PMC7736554 DOI: 10.3389/fneur.2020.581346
Source DB: PubMed Journal: Front Neurol ISSN: 1664-2295 Impact factor: 4.003
Figure 1Selection of trials for inclusion of the systematic review and meta-analysis.
Study characteristics.
| Mugendi-2019 | Kenya | 2015.7–2015.8 | 42 | 59 | NA | 446/NA | NA | NA | 76 | 6 |
| Wang-2019 | China | 1984–2004.9 | 39 | NA | NA | 506/NA | NA | NA | NA | 5 |
| Matchanova-2019 | USA | NA | 50 | 14 | 14 | 583/186 | 22 | 90% | 190 | 4 |
| Saylor-2019 | Uganda | 2013.8–2015.7 | 35 | 47 | 3 | 394/NA | NA | NA | NA | 7 |
| Santos-2019 | Switzerland | 2013.5–2016.11 | 53 | 20 | 13 | 638/180 | NA | NA | NA | 5 |
| Gasco'n-2018 | Brazil | 2013.5–2015.2 | 45 | 32 | 12 | 626/NA | NA | NA | 171 | 7 |
| Haddow-2018 | UK, Denmark, Belarus and Italy | 2011.5–2013.1 | 46 | 16 | NA | 582/290 | 14 | 87% | 119 | 7 |
| Rodriguez-2018 | Mexico | NA | 61 | 14 | 13 | NA/159 | 4 | NA | 133 | 5 |
| Kallianpur-2018 | USA | 2003–2007 | 43 | 19 | 13 | NA/177 | 24 | 73% | NA | 8 |
| Kinai-2017 | Japan | 2014.7–2016.7 | 46 | 5 | 550/163 | 4 | 97% | 91 | 5 | |
| Yusuf-2017 | Nigeria | NA | 37 | 78 | 8 | 369/NA | NA | 100% | 54 | 4 |
| Sacktor-2016 | USA | 2007–2012 | 47 | NA | NA | 589/330 | 13 | NA | 134 | 8 |
| Bloch-2016 | Australia | 2011.10–2012.10 | 49 | 1 | 13 | 592/NA | 4 | 92% | 169 | 6 |
| McDonnell-2014 | England | 2011–2012 | 45 | 0 | 16 | 550/NA | 13 | 88% | 59 | 6 |
| Grant-2014 | USA | NA | 44 | 18 | 13 | 447/187 | 23 | 68% | NA | 7 |
| Bonnet-2013 | France | 2007.6–2009.11 | 47 | 21 | 12 | 515/260 | 6 | 89% | 152 | 7 |
| Ellis-2011 | USA | NA | 43 | 23 | 13 | 420/172 | 26 | 85% | 120 | 6 |
| Heaton-2010 | USA | 2003.9–2007.8 | 43 | 23 | 13 | 420/174 | NA | 85% | 122 | 8 |
| Metral-2019 | German, French and Italian | 2013.5–2016.11 | 55 | 20 | 13 | 634/180 | 17 | NA | 152 | 8 |
Figure 2HAND.
Categorical variables associated with HAND.
| Education | 43.153 | <0.001 | ||
| Below college | 0.62 | 0.584–0.687 | ||
| College and above | 0.315 | 0.258–0.379 | ||
| Nadir CD4 | 0.752 | 0.386 | ||
| Lower than 200 | 0.419 | 0.312–0.534 | ||
| Higher than or equal to 200 | 0.365 | 0.241–0.51 | ||
| Current CD4 | 4.177 | 0.041 | ||
| Lower than 500 | 0.526 | 0.4–0.648 | ||
| Higher than or equal to 500 | 0.352 | 0.275–0.438 | ||
| Study area | 14.261 | 0.001 | ||
| Under-developed | 0.762 | 0.565–0.888 | ||
| Developing | 0.525 | 0.37–0.675 | ||
| Developed | 0.362 | 0.287–0.445 | ||
| Study quality | 0.279 | 0.597 | ||
| Low | 0.45 | 0.363–0.54 | ||
| High | 0.399 | 0.25–0.569 | ||
| Percent female | 0.021 | 0.001–0.042 | 4.331 | 0.037 |
| HCV proportion | 0.041 | −0.009 to 0.092 | 2.495 | 0.114 |
| ART use proportion | −0.026 | −0.057 to 0.017 | 1.118 | 0.29 |
| Age | 0.03 | −0.045 to 0.108 | 0.643 | 0.422 |
Point estimate refers to event rate in categorical moderators and beta in continuous moderators.
Figure 3HAD.
Figure 4MND.
Figure 5ANI.